Ellsworth Advisors LLC Acquires Shares of 6,838 Agilent Technologies, Inc. $A

Key Points

• Ellsworth Advisors LLC acquired 6,838 shares of Agilent Technologies, valued at approximately $800,000, in the first quarter, according to their 13F filing with the SEC.
• Various institutional investors significantly increased their stakes in Agilent Technologies, with Generation Investment Management boosting its stake by 19.8% and GAMMA Investing LLC by an astonishing 15,648.1% in the same quarter.
• Agilent Technologies reported a quarterly revenue of $1.74 billion, exceeding analysts' expectations, alongside an earnings per share of $1.37, matching consensus estimates for the period.

Ellsworth Advisors LLC acquired a new stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 6,838 shares of the medical research company's stock, valued at approximately $800,000.

Several other institutional investors and hedge funds have also bought and sold shares of A. Generation Investment Management LLP lifted its stake in Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after acquiring an additional 824,243 shares during the period. GAMMA Investing LLC lifted its stake in Agilent Technologies by 15,648.1% during the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock valued at $73,375,000 after acquiring an additional 623,264 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Agilent Technologies by 18.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company's stock valued at $448,748,000 after acquiring an additional 604,124 shares during the period. Two Sigma Investments LP lifted its stake in Agilent Technologies by 345.9% during the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock valued at $103,428,000 after acquiring an additional 597,249 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in Agilent Technologies by 141.5% during the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock valued at $109,481,000 after acquiring an additional 548,344 shares during the period.

Agilent Technologies Stock Performance

NYSE:A opened at $124.24 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The company has a fifty day moving average of $119.61 and a two-hundred day moving average of $116.13. The stock has a market capitalization of $35.22 billion, a PE ratio of 29.16, a P/E/G ratio of 3.93 and a beta of 1.24. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm's revenue for the quarter was up 10.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on A shares. Evercore ISI decreased their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a research note on Thursday, August 28th. Leerink Partners boosted their target price on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Wells Fargo & Company boosted their target price on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. Robert W. Baird boosted their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $139.25.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.